Skip to main content
Rheum to Breathe Banner
Worsening Breathlessness in SSc ILD Dr. Aurelie Najm, Glasgow, presents a QD Clinic on worsening breathlessness in systemic sclerosis interstitial lung disease, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/P3MoM7ZmIo
Dr. John Cush @RheumNow( View Tweet )
What you need to know about scleroderma-related lung fibrosis What do you need to know about scleroderma-related lung fibrosis as a practicing rheumatologist? https://t.co/Ezl5G5IZeI https://t.co/zTF4lIYCAJ
Dr. John Cush @RheumNow( View Tweet )

Scleroderma-associated Interstitial Lung Disease

While we know there are certain clinical features serving as predictors that patients with SSc may develop ILD, including diffuse skin disease and serologies such as anti-Scl-70 and Th/To antibodies, it is imperative that clinicians consider that any patient, particularly early in their disease

Read Article
New Multidisciplinary Classification of the Interstitial Pneumonias: ATS/ERS Guideline. https://t.co/HWteOikGXT πŸ«πŸ©»πŸŽžβš”οΈπŸπŸ§ͺπŸ”¬πŸ’‘πŸ“š @ERSpublications @EuroRespSoc @ALATorax @SPLF_SocPneumo @pneumosbpt @NeumoMadrid @SeparRespira @HUReinaSofia @neumoparatodos @Neumosur @NeumoNat https://t.co/GnJjuxMIEm
jpedrokessner @KessnerJp( View Tweet )
Join us Sept 23 @ 7PM ET for the next Rheum to Breathe Journal Club! We’ll dive into two pivotal ILD studies: πŸ“„ FIBRONEER (Nerandomilast in PPF) – NEJM 2025 πŸ“„ RECITAL (Rituximab vs Cyclophosphamide in CTD-ILD) – Lancet Panelists: Dr. Toby Maher, Dr. Shervin Assassi Moderator: https://t.co/BebFhDJ1mM
Dr. John Cush @RheumNow( View Tweet )
When Myositis Hits the Lungs: What Every Rheumatologist Should Know About ILD When idiopathic inflammatory myopathies (IIM) affect the lungs, the consequences can be serious. Interstitial lung disease (ILD) is not only common in IIM, but also one of the leading causes of death, https://t.co/Kxbarq9tiD
Dr. John Cush @RheumNow( View Tweet )
πŸ†• ILD (Part II): advanced insights 🫁 Multidisciplinary management πŸ’Š Treatment strategies πŸ“Š Prognosis & monitoring πŸ§‘βš•οΈ What rheums should know next ⬇️ Download & learn more: https://t.co/XNmbcfqKKF Created by @MithuRheum | For our Rheum to Breathe: ILD Campaign https://t.co/Yhlw3nGsDh
Dr. John Cush @RheumNow( View Tweet )
Definitions for Interstitial Lung Disease: A Consensusfrom the Fleischner Society https://t.co/2r9oS1Eb9k https://t.co/GqKq5E0bmp
Dr. John Cush @RheumNow( View Tweet )
Controversies in ILD This deep dive into controversies in interstitial lung disease explored complex topics including IPAF, methotrexate, systemic autoimmune rheumatic disease vs. connective tissue disease distinctions, and the evolving role of anti-fibrotic therapy. Panelists: https://t.co/ekP1Gg73yj
Dr. John Cush @RheumNow( View Tweet )

Big Fat FDA Pink Slip (9.19.2025)

Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com. Today we cover GLP-1 agonists, acupuncture, what JAKs won’t do & an FDA Pink Slip. 

Read Article
πŸ†• Collaboration with @RheumNow πŸ”΅ 3-Part Series on #InterstitialLungDisease Part2️⃣: Diagnosis & Subtypes of #ILD 🫁 πŸ‘©πŸ»β€βš•οΈ What to look for on Physical Exam πŸ§ͺ Serologic Testing & Diagnostic Workup 🫁 Differentiating ILD Subtypes on Imaging #RheumX #Pulmonology #MedTwitter #MedX https://t.co/X8cJVx2PCV
Mithu Maheswaranathan, MD @MithuRheum( View Tweet )
SARD-ILD: Significant diagnostic and treatment delays Should we be screening all our patients with systemic autoimmune rheumatic disease (SARD) for interstitial lung disease? https://t.co/WyccifEHtY https://t.co/S6X5AhZCjz
Dr. John Cush @RheumNow( View Tweet )
Join us Sept 23 @ 7PM ET for the next Rheum to Breathe Journal Club! We’ll dive into two pivotal ILD studies: πŸ“„ FIBRONEER (Nerandomilast in PPF) – NEJM 2025 πŸ“„ RECITAL (Rituximab vs Cyclophosphamide in CTD-ILD) – Lancet Panelists: Dr. Toby Maher, Dr. Shervin Assassi Moderator: https://t.co/l8EkX2hkLs
Dr. John Cush @RheumNow( View Tweet )
ILD and Mortality in Systemic Autoimmune Rheumatic Diseases Dr. Bryant England, Lincoln, NE, discusses interstitial lung disease and mortality in systemic autoimmune rheumatic diseases (SARDs), as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month https://t.co/wtg9Te6oth
Dr. John Cush @RheumNow( View Tweet )
SARD-ILD and serious infection risk: The elephant in the room Interstitial lung disease (ILD) remains one of the largest unmet clinical needs across many systemic autoimmune rheumatic diseases (SARD). ILD is highly prevalent across systemic sclerosis, mixed connective tissue https://t.co/oxIteGfUTd
Dr. John Cush @RheumNow( View Tweet )
QD Clinic: Application of the ACR CHEST Guidelines to Two Cases Dr. Sindhu Johnson, Toronto, discusses two cases that where the application of the ACR CHEST guidelines for the screening, monitoring and treatment of SSc-ILD and Rapidly Progressive ILD are applied, as part of https://t.co/ntW2WIvJ8c
Dr. John Cush @RheumNow( View Tweet )
Patient Resource: The Hidden Connection - ILD and Rheumatic Disease Dr. Iazsmin Bauer Ventura, Chicago, talks about ILD as a window to systemic disease as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/8rJm4O3hHU
Dr. John Cush @RheumNow( View Tweet )

What you need to know about scleroderma-related lung fibrosis

What do you need to know about scleroderma-related lung fibrosis as a practicing rheumatologist? Here are takeaways from these guidelines and my practice.

Read Article
RA-associated interstitial lung disease or bronchiectasis is assoc w/ increased risk of total and cause-specific mortality. retrospective cohort study using the Mass General Brigham Biobank 221 RA-LD cases (151 RA-ILD, 70 RA-BR). RA-LD higher mortality (34 vs 13/1000PY; HR

Dr. John Cush @RheumNow( View Tweet )

When Myositis Hits the Lungs: What Every Rheumatologist Should Know About ILD When idiopathic inflammatory myopathies (IIM) affect the lungs, the consequences can be serious. Interstitial lung disease (ILD) is not only common in IIM, but also one of the leading causes of death, https://t.co/qRoTr3r84x
Dr. John Cush @RheumNow( View Tweet )
Retrospective study of 201 IPAF (Interstitial pneumonia w/ autoimmune feat.) pts w/ F/U 5.6 yrs. ANA+ 80%, RF+ 25%, CCP+ 14%, 88% Rx w/ IS or antifibrotics. 24% died, 7.5% transplant. Comorbidies were common; mean CCI 3.2; IPAF mortality worsened by

Dr. John Cush @RheumNow( View Tweet )

πŸ†• ILD (Part II): advanced insights 🫁 Multidisciplinary management πŸ’Š Treatment strategies πŸ“Š Prognosis & monitoring πŸ§‘βš•οΈ What rheums should know next ⬇️ Download & learn more: https://t.co/dmhULfqiMj Created by @MithuRheum | For our Rheum to Breathe: ILD Campaign https://t.co/ivvDjxkCvt
Dr. John Cush @RheumNow( View Tweet )
Non-Pharmacologic ILD Care Jon T. Giles, MD, MPH, discusses non-Pharmacologic approaches to ILD treatment and patient care. Sponsored By: Boehringer Ingelheim https://t.co/Mxg9P50m7C #ILD #Rheumatology https://t.co/5wD1K7J1Gq
Dr. John Cush @RheumNow( View Tweet )

SARD-ILD: Significant diagnostic and treatment delays

Should we be screening all our patients with systemic autoimmune rheumatic disease (SARD) for interstitial lung disease? I have been asking myself that question after the recent publication of American Thoracic Society Interstitial Lung Disease screening guidelines. The ATS guidelines, which

Read Article
QD Clinic: Beyond the Numbers in Newly Diagnosed ILD Dr. Eric Dein, Summit, NJ, presents a case of a new patient with interstitial lung disease, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/HLnX5WbbTw https://t.co/SZeI4bqSAm
Dr. John Cush @RheumNow( View Tweet )
×